Why Investors Need to Watch Sarepta Therapeutics Inc.

Sarepta (NASDAQ: SRPT  ) is a popular stock in the Fool community, but its inestors have had a tough run lately, watching shares lose half of their value in the past six months. A late-stage trial failure by a competing drug from GlaxoSmithKline and Prosensa potentially squashed Sarepta's chance for an accelerated approval. Or did it?

Sarepta's management recently met with the FDA to discuss the path forward for eteplirsen. Mothers of boys effected by Duchenne muscular dystrophy are filing a petition, but the small size of the phase 2 trial may not be enough to sway the federal regulators.

On this edition of Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss the possible outcomes for Sarepta, what could affect the FDA's decision-making, and how this catalyst could affect the stock.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (0) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2915340, ~/Articles/ArticleHandler.aspx, 8/28/2014 11:33:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement